New hope for MS patients: can a drug switch stop symptom comebacks?

NCT ID NCT07389590

Recruiting now Symptom relief Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tests whether switching from ocrelizumab to ublituximab can reduce or delay the return of MS symptoms that some patients experience before their next scheduled infusion. Researchers will enroll 50 adults with relapsing MS who have been on ocrelizumab for at least a year and report this 'wearing-off' phenomenon. Participants will be monitored for changes in symptom severity and quality of life over several infusion cycles.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ublituximab
What this could lead to: If it works, this could offer a new option for people with MS whose symptoms return before their next infusion, improving their quality of life.
What could go wrong: This is a small pilot study, so results may not apply to everyone. The benefit may be small or not seen at all, and switching drugs carries its own risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS

Contacts and locations

Locations

Johns Hopkins University
RECRUITING

Baltimore, Maryland, 21287, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.